The digital health company Hims & Hers is launching a bold marketing offensive as its shares face significant pressure. The strategy centers on a controversial Super Bowl commercial designed to ignite a national conversation about healthcare inequality in the United States. This high-stakes move raises a pivotal question for investors: can a loud advertising campaign help stabilize confidence in the equity?
Earnings Report Looms After Regulatory Sector Pressure
The timing of this marketing push is particularly notable given recent headwinds. Hims & Hers shares have declined approximately 19% over the past 30 days, closing Friday at $27.09. The broader digital health sector has also faced challenges since January 31st, when new Medicare rules for telehealth service reimbursements took effect.
While Hims & Hers primarily operates on a direct-to-consumer subscription model, making it less immediately reliant on insurance reimbursements than competitors like Teladoc, the regulatory shift has dampened sentiment across the entire industry. This context places even greater importance on the company’s upcoming financial results, scheduled for release on February 23rd. The fourth-quarter 2025 report must demonstrate that the company’s strategic pillars are working in tandem.
A Campaign Centered on “The Weight Tax”
On Sunday, the company confirmed the launch of a new advertising campaign titled “Rich people live longer.” The spot is set to air during the Super Bowl on February 8th and focuses on disparities in access to healthcare services. According to the announcement, the ad features look-alikes of prominent tech billionaires such as Jeff Bezos and Bryan Johnson.
Should investors sell immediately? Or is it worth buying Hims & Hers?
The campaign is supported by data from a commissioned survey conducted from January 5th to 12th, 2026. It indicates that, on average, U.S. adults spent $12,308 on weight-loss interventions in 2025. Hims & Hers has labeled this financial burden the “Weight Tax.” CEO Andrew Dudum directly links this concept to the company’s mission, stating the goal is to make “proactive healthcare” more broadly accessible and affordable.
Strategic Execution Under Scrutiny
The company now faces the critical task of proving its dual-focused strategy is operationally sound. All eyes will be on two key areas in the forthcoming earnings report:
- GLP-1 Market Expansion: Growth initiatives in the weight-loss segment must translate into convincing financial performance.
- Marketing ROI: The substantial investment in the Super Bowl advertisement needs to yield a measurable increase in subscriber acquisitions and long-term customer retention.
The Super Bowl appearance on February 8th will generate significant media attention. However, the quarterly results on February 23rd will provide the substantive evidence needed to determine whether this aggressive marketing strategy is effectively driving the business forward.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from February 2 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 2.
Hims & Hers: Buy or sell? Read more here...
